MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 31, 2007; DOI: 10.1124/mol.107.040980


0026-895X/08/7302-461-468$20.00
Mol Pharmacol 73:461-468, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.040980v1
73/2/461    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Safaei, R.
Right arrow Articles by Howell, S. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Safaei, R.
Right arrow Articles by Howell, S. B.

Transport of Cisplatin by the Copper Efflux Transporter ATP7B

Roohangiz Safaei, Shinji Otani, Barrett J. Larson, Michael L. Rasmussen, and Stephen B. Howell

Moores University of California San Diego Cancer Center, University of California, San Diego, La Jolla, California (R.S., M.L.R., S.B.H.); Department of Surgery, Hino Hospital, Hino-cho, Tottori Prefecture, Japan (S.O.); and Stanford University, School of Medicine, Stanford, California (B.J.L.)

ATP7B is a P-type ATPase that mediates the efflux of copper. Recent studies have demonstrated that ATP7B regulates the cellular efflux of cisplatin (DDP) and controls sensitivity to the cytotoxic effects of this drug. To determine whether DDP is a substrate for ATP7B, DDP transport was assayed in vesicles isolated from Sf9 cells infected with a baculovirus that expressed either the wild-type ATP7B or a mutant ATP7B that was unable to transport copper as a result of conversion of the transmembrane metal binding CPC motif to CPA. Only the wild-type ATP7B-expressing vesicles exhibited copper-dependent ATPase activity, copper-induced acyl-phosphate formation, and ATP-dependent transport of copper. The amount of DDP that became bound was higher for vesicles expressing either type of ATP7B than for those not expressing either form of ATP7B, but only the vesicles expressing wild-type ATP7B mediated ATP-dependent accumulation of the drug. At pH 4.6, the vesicles expressing the wild-type ATP7B exhibited ATP-dependent accumulation of DDP with an apparent Km of 1.2 ± 0.5 (S.E.M.) µM and Vmax of 0.03 ± 0.002 (S.E.M.) nmol/mg of protein/min. DDP also induced the acyl-phosphorylation of ATP7B but at a much slower rate than copper. Copper and DDP each inhibited the ATP-dependent transport of the other. These results establish that DDP is a substrate for ATP7B but is transported at a much slower rate than copper.


Received August 15, 2007; accepted October 29, 2007

Address correspondence to: Dr. Roohangiz Safaei, Department of Medicine, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819; E-mail: rsafaei{at}ucsd.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics